Sarytogan Graphite Limited (ASX: SGA) has received firm commitments from sophisticated and professional investors to raise $1.8 million (before costs) through a placement of fully paid ordinary shares. The funds will accelerate progress on the company’s Definitive Feasibility Study (DFS) and supplement previously announced conditional placements to EBRD and Kazakh investor Dias Sarsenov.
The placement comprises 20M new shares at $0.09 per share, raising $1.8 million within the company’s existing ASX Listing Rule 7.1 and 7.1A capacity. Investors will also receive one option for every two shares subscribed, exercisable at $0.15 and expiring 30 months from issue. The company will seek quotation of these options subject to ASX requirements.
Sean Gregory, Managing Director of Sarytogan Graphite commented,“We are delighted with the support received to supplement funding to progress this exciting project. This capital raising provides Sarytogan with additional funds towards:
• The Definitive Feasibility Study, including engineering, resource/reserve updates and project design.
• Produce bulk concentrates for downstream test-work and customer qualification.
• Advance downstream flowsheet, including purification, spheronisation and coating programs.
• Progress permitting and early works across mine, plant, and infrastructure sites.
• General working capital to support project development and financing preparation.”
Settlement of the placement shares is scheduled for 2 December 2025, with allotment on 3 December 2025. The offer price represents a 10% discount to the last close of $0.10 and a 15% discount to the five-day VWAP of $0.106 up to 21 November 2025. GBA Capital acted as lead manager.
This funding complements conditional subscriptions of $3.6 million from Dias Sarsenov and $1.4 million from EBRD, which are progressing following receipt of Sub Soil Use Consent from Kazakhstan’s Ministry of Industry and Construction on 31 October 2025.
To read more about this, please visit https://www.sarytogangraphite.com.au/
For more articles like this, please visit https://www.theassay.com/
